Toshihiro Nakajima,
Senior Technical Executive and General Manager of Manufacturing
Toshihiro Nakajima, Ph.D., is a senior technical executive and general manager of manufacturing of GenomIdea, Inc. He is developing a non-replication oncolytic virus (HVJ-envelope vector: HVJ-E) for cancer immune therapy and DNA vaccine for multidrug resistant TB MDR-TB). GenomIdea Inc. (subsidiary of Ishihara Sangyo Kaisha, Ltd.) is an Osaka University-derived campus bioventure company and focuses on the development of the HVJ-E/GEN0101 for virotherapy, cell-based therapy and gene therapy.
Dr. Nakajima studied on the gene regulation of interleukin-6 (IL-6) under Professor Tadamitsu Kishimoto’s supervision and received his Ph.D. in immunology from Osaka University in 1993. He completed his post-doctoral training under Dr. Shizuo Akira’s supervision at Institute for Molecular and Cellular Biology in Osaka University.
Prior to joining GenomIdea, Dr. Nakajima joined Medgene bioscience (AnGes MG later on) in 2000, and was a general manager of the R&D division of AnGes MG.
Preceding AnGes MG, Dr Nakajima was a researcher of Shionogi Institute of Medical Science. He studied on the chemokines and identified a novel chemokine (eotaxin) and it’s receptor (CCR3). He also studied on the characterization of the T-cell tropic HIV receptor (fusin/CXCR4). He was also served on the research staff of the DNAVEC Research Institute (ID Pharma Co., Ltd. later on) and developed a nonpathogenic lentivirus-based vector (pseudotype SIVagm-based vector with VSV or HVJ envelope proteins).
|
|
|
